GNS and Servier Announce AI Collaboration
New partnership will advance multiple myeloma drug discovery and clinical development.
GNS and Servier announced a collaboration to advance drug discovery, translational, and clinical development efforts in Multiple Myeloma (MM).
The collaboration will address key questions about how MM progresses in different patient subpopulations. This work will initially leverage the GNS Gemini Digital Twin for MM developed using the rich clinico-genomic data from the Multiple Myeloma Research Foundation (MMRF) CoMMpass study.
Read more about the new partnership
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
How the NIMBLE Study Supported Adherence With Quarterly Dosing of CemdisiranSeptember 18th 2025
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
